CHGCF News and Press, Chugai Pharmaceutical From 09/15/21

Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Total return for Harding Loevner International Equity Fund net of fees was 5.43% vs. MSCI All Country World ex-US ...

Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Harding Loevner is a Delaware limited partnership. We operate independently of Affiliated Managers Group. The Glob...

The following slide deck was published by Chugai Pharmaceutical Co., Ltd. in conjunction with their 2021 Q2 earnings call. For further details see: Chugai Pharmaceutical Co., Ltd. 2021 Q2 - Results - Earnings Call Presentation

Roche (RHHBY) has been granted Marketing Authorization from the European Commission for Enspryng (satralizumab), created by Chugai Pharmaceutical (CHGCF), as the first subcutaneous treatment option for adults and adolescents from 12 years of age living with anti-aquaporin-4 antibody (AQP...

Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. The current low-quality rally offers an opportunity to look back on the lessons from the last time the markets coo...

Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. The current low-quality rally offers an opportunity to look back on the lessons from the last time the markets coo...

The EMA's Committee for Medicinal Products for Human Use ((CHMP)) has recommended the approval of Roche (RHHBY) unit Chugai Pharmaceutical's (CHGCF) Enspryng (satralizumab), as the treatment for adults and adolescents from 12 years of age living with anti-aquaporin-4 antibody (AQP4-...

Chugai Pharmaceutical Co., Ltd. (CHGCF) Q1 2021 Earnings Conference Call April 22, 2021 05:00 AM ET Company Participants Osamu Okuda - President & Chief Executive Officer Toshiaki Itagaki - Executive Vice President & Chief Financial Officer Tetsuya Yamaguchi - Senior Vice President, H...

The following slide deck was published by Chugai Pharmaceutical Co., Ltd. in conjunction with their 2021 Q1 earnings call. For further details see: Chugai Pharmaceutical Co., Ltd. 2021 Q1 - Results - Earnings Call Presentation

Chugai Pharmaceutical (CHGCF): Q1 GAAP EPS of ¥28.82.Revenue of ¥168.82B (-5.9% Y/Y).Shares +0.79% PM.Press Release For further details see: Chugai Pharmaceutical beats on revenue